AHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
American Healthcare REIT Inc (AHR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows solid financial growth trends and positive analyst sentiment, the technical indicators and insider selling trends suggest caution. The lack of strong trading signals and the neutral options sentiment further support a hold recommendation.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 49.458, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level (52.685), with resistance at 54.121 and support at 51.249.
The company achieved 11.8% Same-Store NOI growth in Q4 2025 and completed over $950 million in acquisitions. Analysts have raised price targets recently, with UBS increasing it to $60 and maintaining a Buy rating. Revenue grew 11.30% YoY in Q4 2025, and the company projects strong Same-Store NOI growth for 2026.
Insiders are selling heavily, with a 148.13% increase in selling activity over the last month. The MACD is bearish, and there is no strong momentum in options data. Additionally, the stock has a 40% chance of declining by 0.91% in the next day.
In Q4 2025, revenue increased by 11.30% YoY to $604.08 million. Net income improved significantly to -$128.84 million, up 305.49% YoY. EPS increased to -$0.72, up 242.86% YoY. Gross margin improved to 20.49%, up 5.73% YoY.
Analysts are generally positive on AHR. UBS raised its price target to $60 with a Buy rating, and Citi increased its target to $55 with a Neutral rating. BMO Capital initiated coverage with an Outperform rating and a $55 price target, citing strong earnings growth potential. Truist adjusted its target to $52 but maintained a Buy rating, expressing optimism about healthcare REITs.
